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The P1Z-gene of a1-antitrypsin as a determinant of the outcome in
PR3-ANCA-positive vasculitis. We have previously demonstrated that a
strong correlation exists between systemic vasculitis with proteinase
3-anti-neutrophil cytoplasm antibodies (PR3-ANCA) and heterozygosity
for a1-antitrypsin (a1-AT) deficiency, PiZ. In the present study we
characterized the PiZ-positive subgroup by laboratory findings, clinical
features and outcome. The series studied consisted of 18 PiZ-positive and
81 PiZ-negative PR3-ANCA patients, comparable in sex ratio, age,
C-reactive protein concentrations and renal function at diagnosis, and
treatment. PiZ-positive patients had a more disseminated disease as
reflected by the number of affected organs (P < 0.01). We found no group
differences in relapse tendency. Overall mortality was 39% (7 of 18) in the
PiZ-positive and 16% (13 of 81) in the non-PiZ group (P = 0.048). When
survival analysis was restricted to 66 patients included in the study at
disease onset, the group difference was significant (P = 0.016). The results
suggest that the subnormal response of plasma u1-AT seen in PiZ-
heterozygotes enhances the risk of dissemination of the vasculitic process
and the risk of a fatal outcome. We consider a1-AT phenotyping to be
justified in cases of PR3-ANCA-positive vasculitis. Treatments decreasing
plasma a1-AT (such as plasmapheresis without plasma replacement) may
be deleterious.
Alpha-1-antitrypsin (a,-AT) is the most abundant anti-protease
in human plasma, the plasma concentration being maintained by
the liver at around 1.3 g!liter. This is controlled by a set of
codominant alleles, constituting the so-called Pi system [1], com-
prising more than 70 different alleles, designated by letters
according to their electrophoretic mobility. The PiZ allele is the
predominant genetic variant responsible for subnormal plasma
concentrations of cs1-AT [11. In the Swedish population, the
frequency of PiZ homozygosity has been reported to be 0.00057,
and that of PiZ heterozygosity 0.047 [1]. The PiZ variant stems
from a point mutation, changing the glutamic acid residue 342 to
lysine, thereby affecting molecular folding and subsequent secre-
tion of the protein. Homozygosity of PiZ results in an increased
risk of early development of pulmonary emphysema and liver
disease [1].
The systemic vasculitides are a group of diseases of unknown
origin, characterized by widespread inflammation in blood vessels.
In systemic vasculitides, especially when they are complicated by
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rapidly progressive glomerulonephritis, it is common that humoral
immune response is directed against myeloid lysosomal enzymes
[2]. This is reflected by the appearance of anti-neutrophil cyto-
plasm antibodies (ANCA) detected by indirect immunofluores-
cence or enzyme-linked immunosorbent assays (ELISA) [3]. Such
an autoantibody, proteinase 3-ANCA (PR3-ANCA), has at-
tracted great interest because of its close relationship to active
Wegener's granulomatosis (WG) [4, 5], a form of systemic
vasculitis preferentially affecting the respiratory system and the
kidney. Interestingly, the natural inhibitor of PR3 is a1-AT, and
PR3-ANCA have been shown to interfere with PR3-a1-AT com-
plex formation [6]. Following the publication of results obtained
in a small French series [7], we recently reported a strong
over-representation of PiZ heterozygosity in a large series of
patients with PR3-ANCA-positive vasculitis [81. A similar rela-
tionship has also been described in a Scottish and in an Austrian
series. In our study we found indications of an increased mortality
among P1Z carriers as compared to the non-carriers.
The nature of the relationship between the PiZ allele and
PR3-ANCA-positive vasculitis is unclear. The aim of the present
study was to analyze clinical features, laboratory findings and
outcome in patients with PR3-ANCA-positive vasculitis with
heterozygous cs1-AT deficiency, as compared to patients with a
supposedly normal a1-AT response. We found the presence or
absence of the PiZ phenotype to be a determinant both of
systemic dissemination and survival.
Methods
Patients
The present series and the selection criteria have been de-
scribed previously [8]. In short, 105 Swedish PR3-ANCA-positive
patient sera were arbitrarily selected for study without knowledge
of clinical data. For the present study 100 hospital medical records
were available for retrospective evaluation.
ELISAs for measuring ANCA and the PiZ variant of a7-A T
Routine ELISAs for proteinase 3-ANCA and MPO-ANCA
were performed as previously described [9]. a1-AT phenotyping
was carried out using ELISA as previously reported [10]. The
assay is based on the use of a monoclonal antibody specific to the
product of the PiZ mutant gene and permits classification of an
individual as heterozygous or homozygous (PiZZ), but cannot
distinguish different types of heterozygotes (PiMZ, PiSZ, or
Pi-nullZ). The ELISA technique has been shown to be as sensitive
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as isoelectric focusing and 100% specific for detection of the PiZ
mutant [111.
Pretreatment laboratory tests
Routine laboratory test results were obtained from the hospital
medical records. If several test results were available the highest
or the lowest, as appropriate, was recorded. The normal range
varies slightly from one laboratory to another, and methods may
have been changed over the years. The current normal ranges at
University Hospital, Lund, are as follows: erythrocyte sedimenta-
tion rate (ESR) 2 to 32 mm/hr, C-reactive protein (CRP) < 5
mg/liter, serum albumin 36 to 48 g/liter, white blood cell count
(WBC) 4.0 to 10.0 >< 109/liter, blood hemoglobin 115 to 166
g/liter, serum creatinine 45 to 116 jmol/liter, serum urea 2.0 to 9.0
mmol/liter and plasma a1-AT 0.9 to 1.7 g/liter.
Organ involvement
To compare groups of patients with regard to systemic dissem-
ination we recorded the involvement of different organ systems.
The presence or absence of symptoms and signs compatible with
vasculitic involvement in the following organ systems were re-
corded: ear, nose and throat (including larynx and paranasal
sinuses); lung; kidney; eyes; skin; joints and muscles; gastrointes-
tinal tract (including the pancreas); liver; nervous system; others
(that is, breast, thyroid gland, testes, heart). The sum of affected
organs over the entire disease period yielded a score ranging from
1 to 10. Upper respiratory engagement was mainly based on
symptoms and sinus X-rays, since most nasal biopsies showed
unspecific chronic inflammation. Lung involvement was mainly
judged from X-ray reports since open lung biopsies were rare in
this series. Kidney involvement was in most cases documented by
biopsy, if not the judgment was based on changes in serum
creatinine concentration and/or urinary findings. Both diffuse
arthralgia and overt arthritis was considered as joint involvement
due to the difficulty to retrospectively distinguish between the two.
If histological or radiological evidence was lacking liver involve-
ment was defined as an elevation of the results of two or more
liver enzyme tests to a level of 50% or more above the upper limit
of the reference range.
Diagnosis and stage of disease at inclusion
The diagnostic procedures have been described before [9]. In
short, patients were first classified as having small vessel vasculitis
or not, and then patients with vasculitis were subgrouped using
the nomenclature of the Chapel Hill consensus conference [131,
and the criteria for Wegener's granulomatosis established by the
American College of Rheumatology [14]. Crescentic and necro-
tizing glomerulonephritis was considered to be part of the vascu-
litic spectrum. The patients were included in the study on the day
the first sample, fulfilling the inclusion criteria, reached the
Wieslab Laboratories, and they were followed until October 1993.
Previously untreated patients or patients started on therapy less
than four weeks prior to inclusion were considered to have been
enrolled at onset of disease. Relapse and remission were defined
as outlined below.
Treatment
Patients were considered to have received immunosuppressive
treatment for vasculitic disease if they had been prescribed any of
the following (alone or in combination): oral steroids ( 20 mg
daily of prednisolone or equipotential doses of other glucocor-
ticosteroids); intravenous pulse-doses of methylprednisolone
( 0.5 g); oral cyclophosphamide (> 50 mg daily) or intravenous
( 700 mg); oral azathioprine (> 50 mg daily); plasmapheresis or
protein A adsorption therapy.
Relapse and remission
Patients manifesting favorable clinical response to treatment
with attenuation of the inflammatory process, and who remained
stable for at least two months, were considered to be in remission.
This definition included a stable or declining serum creatinine, the
absence of new symptoms attributed to vasculitis and absence of
laboratory signs of acute-phase response during the remission
period. No distinction was made between complete and partial
remissions. Relapse was defined as recurrence of symptoms and
clinical findings compatible with vasculitic disease and entailing a
major change in immunosuppressive therapy. A major change in
therapy was defined as reinstitution of steroids or immunosup-
pressive drugs, or a 50% increase or more in dosage of ongoing
treatment. This definition of relapse is thus based on the judgment
of the attending physician. However, the episode was not re-
corded as a relapse if the decision to increase therapy was based
solely on changes in ANCA titer or if it was quickly reversed (for
instance after diagnosis of an infection). A consequence of this
definition was that the earliest time for a relapse to be recorded is
three months after the start of treatment, and that there was
inevitably an interval of three months between two recorded
relapses.
Statistical analysis
Interval scaled variables were compared using the Mann-
Whitney U-test. Proportions were compared using Fisher's exact
test. Survival was estimated using the Kaplan-Meier method.
Survival curves were compared using the Log-rank test.
Results
Of the 105 PR3-ANCA-positive patients arbitrarily selected for
this study, 18 were found to be positive for the PiZ variant of
a1-AT, one homozygote and 17 heterozygotes. Extensive clinical
data were available from medical records in 100 cases, all five
missing cases being PiZ negative. The median age for the PiZ-
positive patients was 60.9 years, as compared to 60.3 years for the
PiZ negative (NS). The PiZ group contained 10 men and 8 women
(a sex ratio of 1.25:1), the corresponding Figures for the non-PiZ
group being 56 and 26 (2.24:1, NS). Clinical characteristics of the
18 PiZ carriers are presented in Table 1.
Pretreatment laboratory tests
The median values of a selected number of routine laboratory
tests performed before the start of treatment are listed in Table 2
(a PiZ-negative patient with non-vasculitic disease was excluded,
see below). The PiZ-positive and PiZ-negative groups were
virtually comparable with regard to severity of inflammation, as
assessed by the increases in WBC, CRP and ESR, and the de-
creases in the serum albumin concentration. As predicted, the
median plasma a1-AT concentration was significantly lower in the
PiZ-positive group (P = 0.001). Group differences in median
hemoglobin and serum creatinine concentrations were non-signif-
icant. Renal function and hemoglobin concentrations tended to
be better in the PiZ-positive group. Of the seven PiZ-positives
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Table 1. Clinical data for 18 PR3 ANCA-positive patients who express the PiZ phenotype of a1AT
No.
Age at
onset of
disease
years/sex
Organ
involvement"
Granuloma
on biopsy
Creatinine
before
start of
treatment Treatmentc
Creatinine
6 months
Maximum after start
creatine of treatment
First relapse Death
(time after (time after
start of start of
treatment) treatment) Cause of
wno1/liter months death
I 21/F NLKESJ H 103 oS C 160 143 90
2 29/F N KESJ x 131 oS C 131 n.a. 62
3 38/Ms KESJGH 0 93 oS C P1 148 119 8
4 39/M NLKESJ 0 83 oS C P1 159 68 36 1130 Leukemia
5 40/F NLK SJ 75 oS C P1 97 79 —
6 43/F N K SJ Ns 85 oS pS C 129 103 —
7 45/F NLKESJ HNsO x 270 oS pS C P1 273 80 35
8 57/M NLK SJ HNsO 106 oS pS C 106 88 116 Pulmonary
emboli
9 59/M NLK SJ HNsO x 70 oS C P1 100 85 —
10 62/M NLKE J H 860 oS pS C P1 Dialysis 248 42 t44 Liver cancer
11 62/M LKE J H 303 oS C P1 Dialysis Dialysis —
12 65/M NLKE J 341 oS pS C Dialysis 208 3
13 65/F NLK J 85 oS pS C 128 108 —
14 71/M NLKE JG 776 oS pS C 906 t tl G bleeding
15 77/M NLK JG 77 oS P1 Dialysis t tO G bleeding,
respiratory
failure
16 77/F N K SJ 156 oS C 172 145 —
17 80/M NLK 1047 oS C Dialysis t4 Active disease,
uremia
18 80/F NLK G 0 x 591 oS C Dialysis 1 II Pneumonia,
uremia
a The only patient homozygous for PiZ.
b Organ involvement is denoted as follows: N, ear, nose and throat; L, lung; K, kidney; E, eye; S, skin; J, joints and mucle; G, gastro-intestinal tract;
H, liver; N, nervous system; 0, other organs (thyroid gland, testis, etc.)
C Treatment regimens are denoted as follows; oS, oral steroids; pS, pulse doses of intravenous steroids; C, cyclophosphamide; P1, plasmapheresis. n.a.
is not available, t is death.
Table 2. Results of routine laboratory investigation before start of
treatment for 99 PR3-ANCA-positive vasculitis patients with
small vessel vasculitis
Group I Group
PiZ Non:PiZ
carriers carriers
P value
Mann-
Whitne
U-testmedian (mean)
Erythrocyte
sedimentation rate mm/hr 95 (92.0) 100 (97.7) 0.36
C-reactive protein mg/liter 154 (173) 153 (156) 0.83
Serum albumin g/liter 30 (28.1) 28 (28.1) 0.97
White blood cells 1O"/liter 11.2 (13.2) 12.4 (13.8) 0.41
Haemoglobin g/liter 108 (105) 99 (99) 0.15
Serum creatinine iiinol/liter 118 (292) 240 (387) 0.23
Serum urea mmol/liter 11.2 (9.3) 20.1 (16.9) 0.19
Plasma a,-ATg/liter 1.6 (1.8) 3.0 (3.2) 0.001
Antinuclear antibodies 9% 15% 1.OC
Rheumatoid factor test 0% 48% 0.03a
Eighteen PiZ gene carriers
Results from all analyses were not available for all patients.
a Fisher's exact test
are compared with 99 non-PiZ carriers.
non-carriers, the medium hemoglobin concentration was 108
versus 99 g/liter, the medium creatinine concentration was 156
versus 250 j.tmol/liter, and the medium albumin concentration was
30.5 versus 28 g/liter. None of these group differences were
significant.
Organ involvement
The degrees of organ involvement in the 18 PiZ carriers are
listed in Table 1, and are schematically depicted (in comparison
with PiZ-negative patients) in Figure 1. The median number of
affected organs was 5.5 for PiZ carriers and 4 for non-carriers
(P = 0.007). Among those with a score of three or below there was
only one out of 25 (4%) who was a PiZ carrier, compared to seven
out of 12 (58%) among those with a score of seven or above. When
analysis of the 'organ involvement-score' was limited to the
patients included in the study at the onset of their disease the
median score for the 13 PiZ carriers was 6 compared to 3.5 for
the 53 non-carriers.
Diagnosis
who underwent a rheumatoid factor test, none had a positive
result, as compared to 48% (14 of 29) of the PiZ-negative patients
(P = 0.03).
When analysis was restricted to the patients included in the
study at the onset of disease the medium CRP concentration was
150 mg/liter for the 13 PiZ carriers versus 168 for the 53
A diagnosis of small vessel vasculitis was made in 99 of 100
PR3-ANCA-positive patients. Biopsy reports recorded small ves-
sel vasculitis in 77 of the 100 patients. In 39 cases there were
biopsy records of extrarenal vasculitis, and in 38 cases the kidney
was the only organ where positive biopsy findings were made. In
a further 22 patients clinical characteristics were convincingly
compatible with vasculitis, findings subsequently supported by a
:r
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favorable response to immunosuppressive therapy. The only
patient without vasculitis had hemolytic anaemia of unknown
origin, and she also had positive ELISA results for several other
autoantibodies (myeloperoxidase-ANCA, antiglomerular base-
ment membrane, etc.), but the Coombs' test was negative. Of the
99 patients with vasculitis, 73 were considered to have WG, of
whom 22% (16 of 73) were heterozygous for the PiZ variant, and
the remaining 26 were considered to have microscopic polyangiitis
(MP), of whom two (7.7%) carried the PiZ variant of a1-AT: one
homozygote and one heterozygote. No patient was found to have
any other form of small vessel vasculitis such as Churg-Strauss
syndrome, Henoch-Schönlein purpura, cryoglobulinemia, or iso-
lated cutaneous vasculitis.
Stage of disease
Two thirds (66 of 99) of the patients were included in the study
at onset of disease. The ANCA-test sample, making these patients
eligible for the study was, with few exceptions, drawn before the
start of treatment. Relapse was the cause of admission in 18 cases
(two PiZ), and in 15 cases PR3-ANCA positivity was detected
during remission (3 PiZ). There was no significant difference
between PiZ-positive and the P1Z-negative groups in the distri-
bution of patients according to disease stage.
Treatment
Of the 99 patients with vasculitis, 97 received immunosuppres-
sive treatment at some time during their disease. The two
untreated patients had MP and neither of them was PiZ-positive.
One who was over 80 years old and had relatively mild symptoms
was included in June 1993, and was thus followed for only four
months. The other untreated patient had carcinoma of the lung
diagnosed shortly after the renal biopsy; the outcome was fatal.
All of the 97 patients received steroid therapy. Intravenous 'pulse'
doses of methyl prednisolone had been administered to 48% (47
of 97) of the patients. Cyclophosphamide treatment had been
initiated in 93 cases (96%); 42 patients (43%) had received
plasmapheresis or protein A adsorption therapy. There were no
significant differences in therapy between PiZ carriers and non-
carriers.
3 6 12 18 24 30 36 42 48
Time, months after start of treatment
Fig. 2. Relapse tendency among PR3-ANCA -positive patients included in
the study at disease onset and in remission three months after start of
treatment. The actuarial relapse-free survival of 8 PiZ-positive patients is
denoted with a dashed line ( —. —) and that of 45 PiZ-negative
patients with a solid line ( ). The outcome variable is relapse, as
defined in the method section, cases where death was attributed to other
causes than disease activity were classified as lost to follow-up. There is no
significant difference between the curves.
Relapses
A total of 72 relapses were recorded, 11(0.61/patient) among
PiZ carriers and 61(0.75/patient) among non-carriers; 54 patients
had no relapse, 29 had one and 16 had two or more relapses. The
median interval from the start of treatment to the first relapse was
20 months. Sixty-six patients were included in the study during the
first attack of their disease. Three months later eight had died and
five had continued to manifest signs of active disease (including 1
untreated patient, see above); thus 53 patients were in remission
according to our definition. Figure 2 shows the relapse-free
survival for these 53 patients. There were no significant differ-
ences in relapse tendency. However, owing to the high mortality in
the PiZ group, it would be difficult to detect any such difference
even if it existed.
Course of renal disease
Before the start of the treatment, 7 (39%) of the PiZ carriers
and 47 (59%) of the non-carriers had a serum creatinine concen-
tration above 160 jmol/liter (NS). As shown in Table 3, six
months later only one of these seven patients was alive with a
serum creatinine below that level. In contrast, ten of the eleven
PiZ patients with creatinine concentrations below 160 jsmol/liter
before treatment remained in this range six months later. The
non-PiZ patients with creatinine concentrations above 160 mol/
liter had approximately equal chances of progression to renal
failure, improvement or persistent impairment of renal function.
Survival
In all, 20 deaths were recorded during the study period, 7 (39%)
in the PiZ group and 13 (16%) in the non-PiZ group (P = 0.048).
Survival analysis using the log rank test, including all patients in
the study and starting at the onset of symptoms, showed PiZ
carriers and non-carriers to differ significantly in this respect (P =
0.029), One third of the patients were included during a relapse or
in remission, which means that they had already survived at least
the first attack of their disease. To avoid this confounding factor,
only survival curves for the patients included at disease onset have
been shown in Figure 3. The difference between the survival
curves is significant (P = 0.016). The two untreated patients are
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Fig. 1. PIZ carriers (ti) and non-carriers •) among PR3-ANCA -positive
vasculitis patients compared with regard to disease dissemination in terms of
the number of organs affected. For definitions see the Methods section.
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Table 3. Outcome of renal function in 18 PiZ-positive and 79 PiZ-negative patients treated for vasculitic diseases associated with PR3-ANCA
(2 untreated patients and 1 non-vasculitic patient are excluded
efore treatment N
6 Months after start of treatment
Unknown statusB Died Dialysis 160 mol/liter <160 j.mol/liter
PiZ
Non-PiZ
160 j.mol/liter
<160 jLmol/liter
160 j.mol/liter
<160 jniiol/liter
7
11
46
33
3
1
4
—
1
—
13
1
2
—
14 (+la)
2
1
9 (+1a)
10 (+3)
23 (+7a)
—
iI
Numbers of patients in different groups based on renal function, as evaluated in terms of serum creatinine (.tmol/liter)
Numbers in brackets indicate estimated level of renal function (deduced from 3-month and/or 12-month values) for patients without documented
serum creatinine between five and seven months after start treatmentbAlive and not in dialysis
0 6 12 18 24 30 36 42 48
Time, months after inclusion in the study
Fig. 3. Survival of PR3-ANCA positive patients included in the study at
disease onset. The actuarial survival counted from inclusion in the study of
13 PiZ positive patients is denoted with a dashed line (— . —. —) and that
of 53 PiZ-negative patients with a solid line ( ). Log rank analysis
showed the two groups to differ significantly (P = 0.016).
included in the analysis. Both among PiZ-negative and among
PiZ-positive patients, early deaths predominantly occurred in
those with an increased creatinine concentration at presentation
(Table 3).
The causes of death for PiZ-positive patients are shown in
Table 1. Eight PiZ-negative patients included in the study at onset
of disease died. Three of them died early in the course due to lung
bleedings and one died of lung cancer (see above). The four
remaining patients in this group all had uremia, the final cause of
death was respectively: myocardial infarction, sudden death,
pneumonia and liver necrosis. Four deaths were recorded in the
'relapse group', all PiZ negative. One patient died of respiratory
insufficiency as a direct consequence of the relapse. One patient
died of pneumonia and two died of cardiac disease with uncertain
relationship to the vasculitis. Two patients in the 'remission group'
died: one PiZ positive (leukemia, treatment related) and one PiZ
negative (cerebrovascular disease).
Discussion
To our knowledge, this is the most comprehensive study
performed on Swedish PR3-ANCA-positive vasculitis patients.
The results in terms of survival rate, outcome of renal function
and relapse rate are consistent with those of previously published
British and American studies of patients with WG or MP [12—15].
Thus, it is reasonable to assume that our series constitutes a
representative sample of such patients. Renal function has been
shown to be an important prognostic factor in WG [16], a finding
consistent with those of the present study. Regardless of a1
phenotype, patients without substantial renal impairment before
the start of treatment had a favorable short-term prognosis.
However, for those with increased serum creatinine concentra-
tions, PiZ heterozygosity was a predictor of poorer outcome. The
causes of death in the PiZ group were diverse. It might be argued
that the PiZ heterozygosity state, by analogy with malnutrition, for
instance, might render the patients more prone to develop
complications. Owing to the small number of deaths in the study,
it is necessary to interpret the difference in survival with caution.
At the time of infection there is a well-known increase in the
plasma a1-AT concentration, probably mediated by cytokines
[17]. Studies in patients with a1-AT-deficiency have shown plasma
concentrations of around 0.3 to 0.5 g/liter to suffice to prevent the
development of pulmonary emphysema [1]. The evolutionary
benefit of the normal plasma concentration of around 1.3 g/liter
and the ability to respond to inflammation is unknown. The most
likely explanation is that a substantial amount of a1-AT is needed
to protect the body from the detrimental effects of serine pro-
teases released from degranulating leukocytes or leukocytes un-
dergoing necrosis. In other words, a1-AT is needed to limit the
extent of inflammation. However, until recently conditions with
moderately decreased a1-AT concentrations have been regarded
as being of minimal clinical importance [1].
Like others, we have reported a relationship to exist between
PR3-ANCA-positive vasculitis and the expression of the PiZ gene
for a1-AT [7, 8, 18]. The reason for this relationship is unclear. It
is not attributable to false-positive test results. PR3-ANCA is not
found in apparently healthy persons with the PiZ gene [18], and
all the PiZ patients in this study were ill. PiZ gene carriership
might either be an etiological risk factor for the initiation of the
disease, or a determinant of the disease course once the patho-
genic process has started. In view of the mode of action of a1-AT,
the second alternative is the most likely. Some support for this
notion can be found in the present results. The increased mortal-
ity of the PiZ-positive patients is, of course, consistent with an
adverse effect on the disease process. A defect in the ability to
limit inflammation is also compatible with the multiplicity of
organ systems affected. The comparable test results for the acute
phase response variables at the time of diagnosis, despite differ-
ences in PiZ gene carriership, is probably due to the patients
having delayed seeking medical attention until the symptoms were
too manifest to ignore. If PiZ carriership affected the CRP
concentration, the carriership would also have affected the symp-
toms that prompted the patient to see a doctor. If the PiZ gene
was linked to initiation of the disease, PiZ-positive patients ought
to be younger at the onset of disease, and they ought to have more
frequent relapses. However, we found the two groups to be
100
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comparable in median age, and we detected no differences in
relapse tendency.
We found the PiZ gene to be present in approximately 20% of
the patients with PR3-ANCA-positive vasculitis, as compared to
the prevalence of 4.7% in the general Swedish population. The
basis of this might be an even stronger correlation with a certain
subgroup. PR3-ANCA occurs in patients with a variety of vascu-
litic syndromes, arbitrarily categorized as WG, Churg-Strauss,
MP, polyarteritis nodosa, etc. The designation of these entities is
based on symptoms and signs rather than etiology or pathogenic
mechanisms. If PiZ is an important factor only in certain condi-
tions, it might prove helpful in providing a basis for classification
more closely related to either pathogenesis or etiology or both. In
this study, PiZ-positive patients were not characterized by any
particular constellation of symptoms. We therefore consider it
unlikely that PiZ-positive vasculitis constitutes a distinct disease
entity. The presence of rheumatoid factor is a common finding in
Wegener's granulomatosis; Fauci and co-workers reported ob-
taining positive test results in 61% (27 of 44) of their series [19].
It should be noted that in the present study none of the PiZ-
positive patients tested for rheumatoid factor had positive test
results, while 48% of the PiZ-negative patients did. The finding
raises the possibility that rheumatoid factor-positive systemic
vasculitis have different characteristics compared to rheumatoid
factor-negative systemic vasculitis. Further studies of the immu-
nogenetic background (HLA-genotypes, Gm-groups, etc.) would
be of interest.
The distinction between an association based on etiology and
an association based on aggravation of inflammation is not only of
academic interest. If a1-AT is important to limit the disease
process, this has therapeutic implications. Today plasmapheresis
is a widely used mode of treatment in rapidly progressive glomer-
ulonephritis, with or without ANCA [20]. After plasma removal,
replacement can be given with either albumin solution, stored
plasma or fresh frozen plasma. Albumin replacement results in a
depletion of a1-AT, even greater than the depletion of IgG
(including ANCA). Plasma replacement or protein A adsorption
therapy do not have this effect. Whether or not these differences
are of clinical importance has not been studied. This might be one
explanation for the contradictory reports of the efficacy of plas-
mapheresis [21].
The presence of PR3-ANCA has been shown to be strongly
correlated with the occurrence of vasculitic disease [2, 22, 23], as
was borne out in the present study where 99 of 100 patients had
some sort of vasculitis. Davenport and co-workers found the
presence of c-ANCA to be of weaker predictive power when
assessing a patient cohort defined by positive ANCA serology
[24]. There are at least three reasons for this discrepancy. First, we
used a higher cut-off level for inclusion in this study than is used
by the laboratory for routine testing. Second, PR3-ELISA is more
specific than immunofluorescence. Third, this study included
some samples collected in 1988, when ANCA testing was limited
to a highly selected group of patients. More extensive testing
might affect the predictive value of the test.
In conclusion, we found that PiZ-carriers with PR3-ANCA-
positive vasculitis have poorer prognosis than non-carriers, al-
though the groups did not differ in established prognostic factors
at presentation, such as age and serum creatinine concentration
[16]. The PiZ carriers tended to have a larger number of organs
affected. The most likely explanation is that a normal ability to
produce and secrete cr1-AT is important to limit inflammation in
these disorders. We recommend that cs1-AT phenotyping be
performed routinely in all new cases of vasculitis with PR3-
ANCA. If a deficiency state is discovered, a treatment that further
lowers the plasma concentration of this protective substance is not
to be recommended.
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